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Abstract 
Background 
The use of observational measures to assess palliative care patients’ level of consciousness may 
improve patient care and comfort. However, there is limited knowledge regarding the validity and 
reliability of these measures in palliative care settings. 
Aim 
To identify and evaluate the psychometric performance of observational level of consciousness 
measures used in palliative care. 
Design 
Systematic review; PROSPERO registration: CRD42017073080 
Data sources 
We searched six databases until November 2018, using search terms combining subject headings and 
free-text terms. Psychometric performance for each identified tool was appraised independently by 
two reviewers following established criteria for developing and evaluating health outcome measures. 
Results 
We found 35 different level of consciousness tools used in 65 studies. Only seven studies reported 
information about psychometric performance, of just eight tools.  All other studies used either ad hoc 
measures for which no formal validation had been undertaken (n= 21), or established tools mainly 
developed and validated in non-palliative care settings (n= 37). The Consciousness Scale for Palliative 
Care and a modified version of the Richmond Sedation-Agitation Scale received the highest ratings in 
our appraisal, but, since psychometric evidence was limited, no tool could be assessed for all 
psychometric properties. 
Conclusions 
An increasing number of studies in palliative care are using observational measures of level of 
consciousness. However, only a few of these tools have been tested for their psychometric 
performance in that context. Future research in this area should validate and/or refine existing 
measures, rather than developing new tools. 
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Key statements 
What is already known about the topic? 
• The European Association for Palliative Care (EAPC) framework for sedative use recommends 
that patients’ level of consciousness should be evaluated as part of their periodical 
assessments during and after administering sedative medication. 
• Observational measures are frequently employed for monitoring consciousness levels in 
settings where sedatives and analgesics are commonly used. 
• The use of observational measures to assess palliative care patients’ level of consciousness 
may improve patient care and comfort; however, little is known about which measures are 
the most appropriate, valid and reliable to use in the palliative care setting. 
What this paper adds 
• An increasing number of studies are using observational tools for the assessment of palliative 
care patients’ level of consciousness. 
• Only eight of these tools have been tested for their psychometric performance with palliative 
care patients in single validation studies, and none have been tested for all measurement 
properties. 
• Most measures of level of consciousness used in primary studies are ad hoc tools for which 
no formal validation has been undertaken, or tools developed and validated in non-palliative 
care settings. 
Implications for practice, theory or policy  
• Clinicians and researchers should be mindful of the limited evidence supporting the 
psychometric quality of existing level of consciousness measures, especially in terms of 
responsiveness, when using such scales in the palliative care setting. 
• Future research should focus on validating and refining existing measures for use in palliative 
care, rather than developing new tools. 
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Background  
Palliative care patients may experience alterations in their level of consciousness, either as a result of 
disease and symptom progression, or as an effect of different pharmacological treatments.1 Clinicians 
may intentionally reduce the consciousness of some patients, especially towards the end of life when 
symptom burden tends to increase, by administering sedative and/or analgesic medication. This 
practice aims to relieve patients’ intractable distress resulting from one or more treatment-resistant 
symptoms.2  
National and international palliative care organisations recommend using sedative medication for the 
alleviation of refractory symptoms at the end of life.3 However, the prevalence and practice of 
sedative use vary considerably according to setting and country.4-6 Nevertheless, the majority of 
clinical practice guidelines on the use of sedatives in palliative care agree that sedative medication 
should be used proportionately, to the extent that distressing symptoms for each individual patient 
are adequately addressed.2,7,8  
Inappropriate use of sedative and analgesic medication may have considerable consequences for the 
care and experience of patients and family members. A survey among palliative care nurses found that 
sedative use was considered insufficiently effective by approximately 40% of the respondents,9 while 
another study reported suboptimal use of palliative sedation performed by general practitioners in 11 
of the 27 described cases.10 Inadequate symptom palliation can be traumatic for patients and a 
significant source of emotional distress for their families.10,11 Conversely, the use of disproportionately 
high doses of sedatives may be equally distressing for relatives due to the impaired ability of the 
patient to interact with family members and the possible risk of hastening death.12,13 
The European Association for Palliative Care (EAPC) framework for sedative use recommends that 
patients’ level of consciousness should be evaluated as part of their periodical assessments during and 
after administering sedative medication. This is in order to avoid the effects of over- or under-sedation 
and fulfil the requirements of proportionality.2 In settings where sedatives and analgesics are 
commonly used, observer-rated measures are frequently employed for monitoring consciousness 
levels.14-16 A review of sedation instruments in intensive care units identified 25 studies describing 
relevant tools.14 Similarly, another review found that numerous tools measuring sedation depth had 
been used in clinical research on procedural sedation.16 Although the authors of these reviews 
concluded that further research into the psychometric performance of the identified measures is 
needed, a number of measures achieved high ratings for validity and reliability in the 
settings/populations in which they were tested. Most of the instruments in these studies comprise a 
single item with a categorical grading representing decreasing levels of consciousness, usually 
assessed by patients’ response to stimulation of increasing intensity. This type of scale structure may 
create overlaps between different consciousness levels which are not necessarily mutually exclusive, 
but provides benefits in terms of simplicity and ease of use, so allowing for repeated administrations 
to be quickly performed and, consequently, enabling the close monitoring of responses to sedative 
and analgesic use.17 Other advantages of using valid and reliable observational measures for the 
assessment of level of consciousness include improved consistency in medication administration, 
better communication among health care professionals, enabling the development of sedation 
guidelines and protocols, and facilitating comparison between research data and findings.18-20 
Occasionally, level of consciousness scores may also provide an indication of disease progression and 
expected survival.21-23  
4 
 
Despite these benefits being highly applicable and relevant to the palliative care context, little is 
known about which measures are the most appropriate, valid and reliable to use with palliative care 
patients. The aim of the present systematic review, therefore, was to i) identify all relevant 
observational level of consciousness tools used in primary research studies, ii) describe their content, 
and iii) critically appraise their psychometric performance. This review was undertaken as part of the 
sedation work package of I-CAN-CARE (Improving care, assessment, communication and training at 
the end-of-life), a Marie Curie funded research programme on prognosis and sedative use in palliative 
care.  
  
Methods  
This review was reported in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) Statement,24 and the review protocol published in the International 
Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD42017073080). 
Search strategy 
A four-step search strategy was employed (Table 1). An initial broad search was performed to identify 
primary research studies reporting the use of observational level of consciousness measures and 
produce a list of search terms. Six databases were then systematically searched using a combination 
of subject headings and free-text terms for palliative care, measurement instruments and sedative 
use, adjusted for each database. Subsequently, the reference lists of all included papers were hand-
searched for relevant publications. When eligible articles were identified, the process of backward 
reference searching was repeated until no more relevant publications could be located. The same 
method was applied for finding newer studies citing the included papers. Lastly, authors of conference 
abstracts meeting inclusion criteria were contacted for full-text publications. Where relevant data was 
missing from included papers, authors were also contacted. 
Eligibility criteria 
Full-text publications of primary studies (prospective or retrospective; patient-based or clinician-
based) describing the use of observational measures (validated or ad hoc) for the assessment and/or 
monitoring of level of consciousness/sedation depth in adult palliative care patients, were included.  
We excluded non primary studies, such as systematic reviews, and studies providing no information 
about sample size. Due to resource constraints, non-English language publications were also excluded.  
Study selection 
After removing duplicates 11,938 titles and abstracts were screened against eligibility criteria (AMK). 
A second reviewer (EM) independently screened a random 10% selection. The inter-reviewer 
agreement for the initial title and abstract screening was κ= 0.71. Full-text publications which 
potentially met inclusion criteria after first screening were each independently assessed for eligibility 
by two reviewers from a group of six (AMK, JS, EM, SM, BV, PS). Discrepancies at each stage of study 
selection were resolved through discussion.  
Data extraction 
We extracted the following information for each included study into a standardised form: first author, 
date of publication, country of origin, study aim(s), setting, sample size and participant characteristics. 
For each measure identified: tool name, measurement aim/purpose, number of subscales and items, 
and response options were extracted.  Data on the psychometric performance of instruments, where 
available, were also extracted. 
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Psychometric performance of included measures 
We used a checklist (Table 2) to evaluate the psychometric performance of included measures. This 
checklist drew on that developed by Zwakhalen et al.25 with some modifications, following discussion 
between AMK and BV, based on established criteria for developing and evaluating health outcome 
measures.26-28 
The psychometric properties appraised include the reported validity, reliability and responsiveness of 
measures. In addition, the feasibility and origin (source) of tool items were also evaluated. 
Validity of an instrument was defined as an assessment of the extent to which it measures what it 
purports to measure.26 It is generally understood that there are four types of validity; we assessed 
three of these: (1) content validity: the degree to which the construct of interest is comprehensively 
represented by the measure items, assessed through the extent of involvement of the target 
population in item selection and the provision of a clear description of the concept that the instrument 
is intended to measure;28  (2) construct validity: correlation of the level of consciousness scale with 
other instruments that are known to measure the same construct. Pearson’s or Spearman’s 
correlation coefficient of 0.6 or above was considered acceptable in this review;25 (3) structural 
validity: assessed through the degree of variance explained by factor analysis. There is no agreed “gold 
standard” for measuring level of consciousness in palliative care, so we did not assess the fourth type 
of validity, (4) criterion validity: the extent to which a proposed new measure correlates with another 
instrument generally accepted to accurately measure the construct of interest (“gold standard”).26 
Reliability refers to the overall consistency and reproducibility of a measure.26 Four types of reliability 
estimates were included in our assessment criteria: (1) homogeneity (internal consistency), assessed 
through Cronbach’s alpha coefﬁcient; (2) inter-rater reliability; (3) intra-rater reliability; (4) test-retest 
reliability. The common statistical methods for evaluating the latter three properties are intraclass 
correlation coefficient (ICC) for continuous measures and Cohen’s kappa for nominal/ordinal 
measures.28 We took values of less than 0.6, between 0.6 and 0.8, and greater than 0.8 as indicative 
of low, adequate, and high reliability, respectively. 
Responsiveness is the ability of an instrument to detect clinically meaningful changes over time in the 
construct measured. The most common approaches to assessing responsiveness are the correlations 
of change scores for an instrument over time with changes in other available variables, and the area 
under the receiver operator characteristic (ROC) curve (AUC).26,28 
Feasibility is described as the user-friendliness of a measure in terms of administration and 
processing.26 The burden on staff of collecting and processing data is an important parameter to 
consider when selecting a tool for use in clinical practice or for research purposes.26  
Origin of items refers to whether the measure items were specifically developed for use with the 
target population, modified, or taken from a scale developed for another population.25 
Evidence of psychometric performance was categorised according to the above mentioned criteria. 
For each property, measures were scored according to the following scheme: 2 if the property was 
evaluated and fully met criteria; 1 if criteria were partially met; and 0 when criteria were not met. If a 
property was not evaluated/not reported or the information provided was unclear, a rating was not 
given. Psychometric properties were independently evaluated by two raters (AMK, EM), achieving a 
high initial agreement (κ= 0.91). Raters conferred over discrepancies until full consensus on ratings 
was reached. 
 
Results  
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The database search yielded 13,827 results. After removing duplicates and initial screening of titles 
and abstracts, 491 potentially eligible articles remained which were examined in full. Of these, 55 met 
criteria for inclusion. A further 10 eligible studies were identified through forward and backward 
citation searching, resulting in 65 included studies (see Figure 1). Only seven studies provided data on 
the psychometric performance of level of consciousness tools in the palliative population;  21 studies 
presented information on ad hoc measures (i.e. those developed specifically for the purposes of 
individual studies); and 37 reported using established scales, the majority of which had been validated 
in non-palliative care settings. Table 3 presents a summary of study and measure characteristics. 
Description of included studies 
Morita and colleagues41,42 published two articles in which separate analyses of data collected from a 
single study were performed. Similarly, Barbato et al.,53,54 Campbell et al.,57,59 Claessens et al.1,97,98 and 
Van Deijck et al.48,49 reported distinct findings from one study in two or more papers. Each of these 
papers described discrete study aims and outcomes, so we defined them as separate studies. A large 
number of studies reporting on level of consciousness measures have been published recently, with 
26 of the 65 (40%) included studies published after 2013. 
Most included studies were patient-based (n= 58), with recruitment and data collection conducted 
prospectively (n= 49). In eight studies some or all relevant data were obtained retrospectively from 
patients’ medical records,4,35,38,41,42,55,79,90 while in one study patients were recruited both 
prospectively (on admission) and retrospectively (after death).37 Another study reported mixed 
methods for data collection, a prospective quantitative survey and semi-structured interviews with 
general practitioners involved in the practice of palliative sedation.10 Six studies used questionnaires 
as a means of data collection.31,43,46-49 In these, researchers asked clinicians (physicians (n= 4)43,47-49 or 
nurses (n= 2)31,46), to provide information about patients under their care who had received sedative 
medication.  
Studies were mainly conducted in a single setting (n= 36); principally hospices, palliative care units, or 
hospitals. Nine studies involved home care patients,4,10,31,56,62,67,81,84,90 and an equal number included 
nursing home participants.31,37,44,46,48-50,92,93 One study included patients recruited from a cancer 
centre.81 
Sample size varied considerably (median: 132 participants, IQR: 44-266). The most prevalent diagnosis 
among study participants was cancer (n= 29). Other reported diagnoses included dementia (n=3)37,44,50 
and interstitial lung disease (n= 1).79 Thirty-two studies reported mixed diagnoses or did not provide 
this information. Patients in almost all studies were at an advanced or an end stage of disease. 
Reflecting the wide diversity of study aims, level of consciousness tools in each study were employed 
to serve a number of distinct purposes. The most frequently reported were: to assess/monitor 
sedation depth after palliative sedation initiation (n= 29); to assess effects or side-effects of opioid use 
(n= 7);29,34,45,54,56,81,91 to evaluate signs/symptoms of impending death (n= 8);21-23,37,42,60,61,79 to examine 
associations between level of consciousness and discomfort or other symptoms (n= 6).40,44,50,60,61,64 It 
is noteworthy that only four studies sought to validate level of consciousness instruments in the 
palliative care setting.18,73,87,93 Of these, only one aimed to develop a new tool.18 
Description of identified measures 
A total of 35 different measures assessing level of consciousness were described in the articles 
included in this review. Only eight were measures for which evidence of psychometric quality in the 
palliative setting was available. Fifteen were established instruments or single items taken from 
compound scales validated as a whole, and 17 were tools constructed for individual study purposes 
(ad hoc measures). Information on psychometric performance in palliative care was provided for five 
of the 15 established measures, therefore there is an overlap between the first two described 
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categories (see Figure 2). Across all categories, the tool most frequently employed was the original 
RASS or its modified versions (n=17).10,21,35,51,53-55,64,70,72,73,77,84,86,87,91,93 
Three of the ad hoc measures were modified versions of existing tools: the Glasgow Coma Scale (GCS), 
32,33 Richmond Sedation-Agitation Scale (RASS)19,35 and Riker Sedation-Agitation Scale.23,39 All other ad 
hoc measures comprised unique tools. None of the reported ad hoc measures had been formally 
validated before use.  
The established measures most commonly used were the RASS19 (n= 11)10,21,51,53-55,64,70,77,84,91 and 
Ramsay Sedation Scale (RSS)52 (n= 7)4,65,78,84,88-90. Most established measures had been developed and 
validated for use in settings other than palliative care; mainly the intensive care unit. The studies with 
palliative care patients in which these measures were used provided no information on their validity 
or reliability. 
Two of the existing measures used for the evaluation of level of consciousness consisted of items 
extracted from multi-item tools developed to assess constructs other than level of consciousness (i.e. 
the conscious level item of the Communication Capacity Scale5,76,83 and the sedation item of the Pain 
Flow Sheet81,82). These tools had been evaluated psychometrically in palliative care settings, but 
validity and reliability have only ever been established for each measure as a whole, not for the 
individual items measuring levels of consciousness.  
Almost all of the described measures consisted of one item with a range of mutually exclusive scoring 
options (n= 27), usually involving observation of spontaneous activities, such as eye opening, or 
responses to auditory and/or tactile stimuli performed in a logical progression. The majority of these 
tools (n= 23) evaluated a single construct: consciousness in terms of arousal, while the remaining 
measures (n=4) incorporated the assessment of agitation into single scales for 
consciousness/sedation.  
Evidence of psychometric performance was provided for: the Minnesota Sedation Assessment Tool 
(MSAT),93,94 RASS,19,93 Vancouver Interaction and Calmness Scale (VICS),93,95 Sedation score proposed 
in the Guideline for Palliative Sedation of the Royal Dutch Medical Association (KNMG),93,96 Modified 
RASS,19,73 Richmond Agitation-Sedation Scale- Palliative version (RASS-PAL),19,87 GCS, 1,33,97,98  and 
Consciousness Scale for Palliative Care (CSPC).18 
Dutch versions of original English language measures were created by researchers for the MSAT,93,94 
RASS,19,93 VICS93,95 and GCS.1,33,97,98 The RASS modified by Benitez-Rosario and colleagues73 was 
translated and further adjusted for use with Spanish palliative care patients. Modifications to the 
original RASS19 included the removal of descriptors relating to the mechanical ventilation of patients 
and a clarification to the scoring instructions addressing the possibility that restless behaviour may be 
present in patients who are not fully alert. Similarly, Bush et al.87 reported performing minor changes 
to the RASS19 when testing its psychometric performance in the palliative care setting. The CSPC was 
validated in its source language (Portuguese) and, subsequently, translated by its authors into 
English.18 
Appraisal of psychometric performance 
Evidence regarding structural validity, test-retest and intra-rater reliability was not provided for any 
of the evaluated measures, so we do not present findings relating to these properties. The CSPC18 and 
a modified version of the RASS73 achieved the highest ratings in our quality appraisal, but our 
evaluation was based on evidence obtained from just one study for each measure. Table 4 provides a 
summary of the quality appraisal process for each instrument. 
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Content validity 
All studies provided a clear description of the construct measured by the reported instruments. 
However, the involvement of the target population in selecting or modifying scale items was described 
only for three of the eight evaluated measures; the CPSC,18 RASS-PAL,87 and Modified RASS.73 One 
study18 reported receiving feedback on the content of the CPSC from seven palliative care doctors and 
nurses at the construction stage on the scale. Likewise, the input of palliative care professionals guided 
the modification of scale items for the RASS-PAL87 and RASS modified by Benitez-Rosario and 
colleagues.73 
Construct validity 
Information on construct validity was available for six of the eight included measures; the MSAT,93,94 
VICS,93,95 RASS,19,93 KNMG,93,96 CPSC,18 and Modified RASS.73 For these, construct validity was evaluated 
through the correlation of the tested instrument with others that were assumed to measure the same 
construct (convergent validity). Discriminant validity was not assessed for any tool.   
Correlations were reported per subscale for the MSAT and VICS.93-95 The MSAT arousal subscale 
performed better than the motor activity subscale with Spearman’s correlation coefficient ranging 
from 0.48 to 0.83, depending on the measure with which it was correlated (RASS, KNMG, VICS). Low 
to moderate correlations were reported for the motor activity subscale of the MSAT (ρ= 0.42-0.61). 
Mostly moderate correlations were found between both subscales of the VICS with other tools 
measuring level of consciousness (interaction subscale: ρ= 0.31-0.72, calmness subscale: ρ= 0.31-
0.57).93-95 
Construct validity of the RASS and KNMG was supported by moderate-strong associations when 
compared with corresponding instruments.19,93,96 Strong correlations with other tools measuring level 
of consciousness were reported for the Modified RASS and CPSC.18,73 Spearman’s correlation 
coefficient for the Modified RASS to the GCS33 ranged from 0.81 to 0.85, and 0.82-0.89 when 
compared with the RSS,52 depending on the group of professionals scoring the scales (palliative care 
physicians or medical residents).73 Likewise, the CPRS correlated highly with a 100 mm Visual Analogue 
Scale (VAS) anchored in the terms “awake” and “unarousable” (ρ= 0.94-0.95) and with the GCS (ρ= 
0.82-0.85).18,33 
Homogeneity (internal consistency) 
As the aim of some of the studies was not to address unique measure characteristics, homogeneity 
was evaluated for only one of the appraised measures, the CPRS.18 For this instrument, the reported 
Cronbach’s alpha coefficient was very high (α= 0.99).18 
Inter-rater reliability 
Intraclass correlation coefficient (ICC) or weighted Cohen’s kappa were used for the assessment of 
inter-rated reliability in all of the included studies. From the tested measures, inter-rater reliability 
was found to be high for the CSPC (ICC= 0.99),18 GCS (ICC= 0.807),1,33,97,98 RASS-PAL (ICC= 0.84-0.98)87, 
and Modified RASS (κ= 0.85-0.95).73 Moderate correlations within paired observational assessments 
were reported for the RASS (ICC= 0.71-0.73)19,93 and KNMG (ICC= 0.66-0.71).93,96 Of the MSAT  and VICS 
subscales, the VICS interaction scale performed best with intraclass correlation coefficient ranging 
from 0.77 to 0.85, followed by the MSAT arousal scale (ICC= 0.59-0.64).93-95 Depending on the time 
interval between paired assessments, Cohen’s kappa coefficient ranged from 0.44 to 0.54 for the 
MSAT overall quality of sedation scale, suggesting low agreement between scale assessors. No 
correlations were found for the MSAT motor activity and VICS calmness subscales.93-95 
Responsiveness 
Change scores indicating clinically meaningful change over time in consciousness/sedation levels were 
not described for any of the appraised measures. Bush and colleagues87 provide some information on 
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the floor and ceiling effects for the RASS-PAL but it is not adequate for the assessment of 
responsiveness.  
Origin of items 
Items for half of the measures for which evidence of psychometric performance was available, 
originated from scales developed for non-palliative care patients. Specifically, aspects of the 
measurement properties of the Dutch versions of the MSAT,93,94 VICS,93,95 RASS19,93 and GCS,1,33,97,98 
were appraised by study authors adopting the original items of these scales without assessing their 
appropriateness for the palliative care setting. 
For the other half of the scales, items were either modified (RASS-PAL,87 Modified RASS73) or 
particularly developed (KNMG,96 CSPC18) for monitoring palliative care patients’ level of 
consciousness. 
Feasibility 
In a comparison for user-friendliness between the Dutch versions of the RASS,19 MSAT94 and VICS95, 
Arevalo et al.93 reported that most palliative care professionals found RASS the least time-consuming, 
clearest, and easiest to use. Acceptable ratings were achieved for the MSAT, while the VICS was 
evaluated as the least clear and easy to use among the three tools. The RASS-PAL,87 CSPC18 and 
Modified RASS73 were also regarded as feasible and useful tools by healthcare professionals. 
 
Discussion  
Main findings  
This systematic review aimed to identify, describe, and appraise the psychometric performance of 
level of consciousness measures used in palliative care. We found 35 different level of consciousness 
tools used in 65 studies. Evidence of psychometric performance, however, was available for only eight 
of these instruments. Two of these eight tools were specifically developed for palliative care 
populations (CSPC,18 KNMG96), two were versions of an existing tool (i.e. the RASS19) modified for use 
in palliative care (Modified RASS,73 RASS-PAL87), and four were measures developed for different 
populations, tested for aspects of validity and/or reliability in the palliative setting (GCS,1,33,97,98 
MSAT,93,94 RASS,19,93 VICS93,95). None of these tools had been evaluated across all relevant 
psychometric properties; hence no measures appraised had been fully validated. 
The majority of measures identified were either ad hoc tools for which no formal validation had been 
undertaken (n= 17), or tools developed and validated mainly in non-palliative care settings (n= 
15).  This widespread use of non-validated measures raises questions regarding the methodological 
robustness of studies and the quality of reported evidence,99 not least because, although tools’ 
psychometric performance may have been investigated in specific contexts, this does not transfer to 
other settings.100 It is therefore essential, as with any measures to be used in palliative care, that tools 
assessing level of consciousness should be thoroughly validated with palliative care patients in order 
to be certain that they are reliable for this population.  
Most measures identified sought to measure consciousness in terms of wakefulness, and, therefore, 
mostly (n= 23) comprised one item with a range of levels describing patients’ responses to verbal 
and/or physical stimulation. Apart from consciousness, a small number of tools (n= 4) included the 
assessment of agitation, as a domain related to sedative and analgesic use, in a single scale. These 
tools have been criticised for various reasons, including the lack of clarity in the definition of different 
consciousness levels, and the poor standardisation of employed stimuli.16,18 Moreover, the assessment 
of patients presenting decreased consciousness and restlessness at the same time may be 
compromised when both conditions are evaluated on the same scale.14,16 Nevertheless, the most 
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commonly employed measure was the RASS19 (a tool assessing sedation and agitation on a single-item 
scale) or modified versions of it (n= 17). An explanation for this may be that the RASS requires minimal 
training and can be quickly and easily administered at the bedside.19 These are particularly desirable 
features for a scale intending to measure level of consciousness, an often unstable characteristic, in 
clinical environments where patients are cared for by professionals of different backgrounds, as in 
palliative care.18 
Limited information was available on the measurement properties of tools, thus making it difficult to 
draw definitive conclusions about their psychometric performance. Our evaluation was based on 
evidence obtained from a single study, rather than a group of studies, for each measure. Some studies 
did not aim to specifically develop and/or validate level of consciousness measures.1,93,97,98 As a result, 
these studies assessed only certain psychometric properties on each occasion, and no tools were 
tested across all measurement properties. Our quality assessment outcomes should be treated with 
caution, therefore, until further evidence on the psychometric performance of the appraised 
measures becomes available. 
Information on inter-rater reliability and internal consistency was provided by all studies, with most 
tools performing adequately on both properties. Due to the lack of a “gold standard” level of 
consciousness measure in palliative care, criterion validity could not be assessed. Instead, in three 
studies the tested tools were compared with other instruments known to measure level of 
consciousness.18,73,93 However, although the reported correlations between the assessed measures 
and other comparable tools were acceptable to high, the reference measures were not themselves 
tested for their psychometric performance in a palliative care context.  
No publications provided any information regarding test-retest or intra-rater reliability, although all 
studies described collecting data at more than one time point. This might be explained by the lack of 
stability of the construct measured, i.e. palliative care patients’ fluctuating level of consciousness. 
Thus, the assessment of these psychometric properties may not be feasible for level of consciousness 
measures in this population. 
The measures with the highest ratings in our appraisal were the CSPC,18 a tool specifically developed 
to measure level of consciousness in palliative care, and a version of the RASS modified for use with 
palliative care patients.73 However, the only information available about the psychometric 
performance of either was restricted to that of initial validation studies, and  insufficient for assessing 
all appraised measurement properties. Palliative care clinicians and researchers should be mindful of 
these restrictions when using level of consciousness measures, therefore. 
Our findings agree with those of previously published reviews. In their review of level of sedation 
instruments, De Jonghe et al.14 report that responsiveness had not been tested for any of the scales 
identified. They comment that responsiveness is an important measurement property because it can 
inform the titration, initiation and withdrawal of sedative drugs.14 Apart from these benefits, a 
measure that can reliably detect changes in patients’ level of consciousness over time may enable the 
longitudinal evaluation of patients and provide a useful outcome measure for palliative care research. 
Nevertheless, like De Jonghe et al.,14 we did not find adequate evidence to appraise responsiveness in 
our review. When seeking to determine clinically important changes in patients’ status or evaluate the 
effects of medical interventions it may be problematic to use measures that do not demonstrate 
satisfactory responsiveness, since changes in scores may result from measurement error rather than 
true changes in patients’ consciousness levels. Thus, it is important that clinicians and researchers are 
aware of the limited evidence regarding responsiveness when choosing measures to evaluate 
treatment/intervention outcomes or interpreting level of consciousness scale scores. In order to 
enable clinical assessment and decision-making, and support the testing of new interventions, future 
studies that seek to develop new level of consciousness tools or validate existing ones should aim to 
provide strong evidence on the responsiveness of these measures. 
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Brinkkemper et al.101 identified seven scales measuring level of awareness reported in primary studies. 
Of these, similar to our findings, a significant proportion were ad hoc measures, while the RASS19 was 
the most commonly used of the established scales. Brinkkemper et al.101 found only one tool, the 
Communication Capacity Scale (CCS),76 for which information on psychometric performance was 
available. Although the authors presented this information, they did not formally evaluate the 
psychometric quality of the CCS76 because this was outside the scope of their review. Our search 
identified the CCS,5,76,83 but it was excluded from our quality appraisal because the scale used for the 
assessment of consciousness level constitutes an individual item extracted from a compound measure 
for assessing the ability of terminally ill patients to communicate that was developed and tested as a 
whole. Hence, the psychometric evidence provided pertain to the CCS76 measure as a whole, not its 
individual items.  
Brinkkemper et al. identified a substantially smaller number of tools than we did, because their review 
focused specifically on the effects of palliative sedation. Our inclusion criteria were broader, allowing 
the inclusion of studies reporting the use of observational measures regardless of the purpose for 
which these were employed. Moreover, an increasing number of studies using level of consciousness 
have been published since the publication of their review in 2013. Twenty-six of the 65 included 
studies in our review (40%) have been published since 2013. A possible explanation for this upward 
trend may be the recent publication of high impact guidelines recommending the use of observational 
scales for the monitoring of level of consciousness of palliative care patients receiving sedative 
medication.2,102 
Strengths and limitations  
A strength of this systematic review is the comprehensive yet broad search strategy followed, 
including six databases without applying date restrictions. We also performed a thorough backward 
and forward citation search for all included articles and contacted abstract authors in order to ensure 
that all relevant publications were identified. A limitation is that we included only English language 
publications. It is possible that studies providing evidence on measurement properties of translated 
versions of tools were missed. We are aware of at least one validation study which was excluded from 
this review due to language restrictions.103 
Two reviewers (AMK, EM) independently performed the appraisal of the psychometric performance 
of identified measures against well-defined quality criteria. Nevertheless, comparability of evidence 
was hindered by the heterogeneity of studies reporting data on psychometric properties in terms of 
setting, sample size, participant population, study design and objectives, and of the purposes for which 
tools were employed on each occasion. Our evaluation, therefore, was based on the limited published 
evidence from individual studies for each appraised measure. 
 
Conclusion  
This systematic review demonstrates that although an increasing number of studies are using 
observational level of consciousness measures, only a few of these tools have been tested for their 
psychometric performance in the palliative care setting, and none across all relevant measurement 
properties. The CSPC and a modified version of the RASS achieved the highest ratings in our appraisal, 
but further evidence on their measurement properties is needed before either can be recommended 
as valid and reliable measures for use in palliative care practice and research. Future research in this 
area should use, and seek to further validate and refine existing level of consciousness measures, 
rather than developing new tools or using ad hoc instruments. 
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CENTRAL: Cochrane Central Register of Controlled Trials; CINAHL: Cumulative Index to Nursing and Allied Health Literature; WoS: Web of 
Science. 
Figure 1: PRISMA flow diagram of study selection process24 
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(n = 720) 
-Duplicate record n = 76 
-Language n = 12 
Measures not used to assess level of consciousness n = 392 
    
     
 
 Full-text articles assessed 
for eligibility 
(n = 491) 
Duplicate records excluded 
(n = 1,889) 
Records screened on title 
(   11 938) 
 
 
Records screened on abstract 
(   1 211) 
 
 
Records excluded 
(n = 10,727) 
Records excluded 
(n = 436) 
-Conference abstract n = 110 
-Duplicate Record n = 6 
-Language n = 30 
-Population/Setting n = 11 
     
           
      
       
 
Full-text articles included 
after forward/backward 
citation searching 
(   10) 
Total number of full-text 
articles included  
(n = 65) 
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Figure 2: Number of identified studies and measures by instrument category 
  
Final number of studies 
included
(n = 65)
Studies reporting on  
psychometric properties 
of measures
(n = 7)
Measures assessed for 
psychometric 
performance in PC
(n = 8)
Studies using established
measures
(n = 37)
Established measures 
described
(n = 15)
Studies using ad hoc 
measures
(n = 21)
Ad hoc measures 
described
(n = 17)
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Table 1: Search strategy and eligibility criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Search Strategy 
Step 1: Broad search of 
relevant literature 
i) Identification of relevant publications in PsycINFO and MEDLINE  
ii) Compilation of text words contained in title, abstract and authors’ keywords, 
and database index terms, to produce a list of search terms 
Step 2: Systematic database 
search 
Databases:  
1. CENTRAL, 2. CINAHL, 3. Embase,  
4. MEDLINE, 5. PsycINFO, 6. WoS 
 Dates:  
Database inception – 14 November 2018 
 Restrictions: 
No language or other restrictions applied 
 Search terms (used in MEDLINE and modified for other databases): 
1. Self Report/  
2. Checklist/  
3. (tool* or assess* or survey* or question* or measur* or method* or scale* 
or checklist* or rating* or test* or instru* or inventor* or technique* or 
monitor* or observ* or rate* or function* or scoring system* or 
outcome*).mp.  
4. 1 or 2 or 3 
5. Palliative Care/  
6. exp Terminal Care/  
7. Hospices/  
8. (palliat* or terminal* or endstage or hospice*).mp.  
9. (end adj3 life).mp.  
10. (care adj3 dying).mp.  
11. ((advanced or late or last or end or final) adj3 (stage* or phase*)).mp.  
12. 5 or 6 or 7 or 8 or 9 or 10 or 11  
13. ((continuous or deep or intermittent or intermediate or respite or mild) 
adj3 (sedat* or an?esthe*)).mp. 
14. Deep Sedation/  
15. Conscious Sedation/  
16. sedat*.mp.  
17. 13 or 14 or 15 or 16 
18.   4 and 12 and 17 
Step 3: Citation searching i) Backward citation searching (hand-searching reference lists of included 
publications), and ii) forward citation searching (hand-searching studies citing 
included publications through Google Scholar) were repeated until no more 
relevant publications could be located 
 
Step 4: Contacting authors i) Authors of conference abstracts meeting inclusion criteria contacted for full-
text publications 
ii) Authors of included papers contacted where relevant data was missing from 
publications 
 
 
 
 
 
Eligibility criteria 
Inclusion criteria 1. Primary research studies 
2. Full-text research articles 
3. English language publications 
4. Studies reporting the use of observer-rated measures 
5. Studies conducted with adult (>18) palliative care patients 
6. Scales assessing and/or monitoring depth of sedation/consciousness level 
Exclusion criteria 1. Non-primary studies, including systematic reviews 
2. Opinion articles, editorials, book chapters 
3. Case report studies and studies providing no information about sample size 
4. Non-English language publications 
5. Studies with non-adult (<18) palliative care patients 
6. Studies reporting the use of patient/self-reported measures 
7. Scales measuring drowsiness or somnolence 
8. Studies reporting on the use of binary-response measures 
CENTRAL: Cochrane Central Register of Controlled Trials; CINAHL: Cumulative Index to Nursing and Allied Health Literature; WoS: Web of 
Science. 
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Table 2: Quality criteria for measure appraisal  
Domain Property Score Description 
 Number of 
participants 
 
2 N ≥ 100 and the number of palliative care patients included was relative to the number of items/variables or 50 < N < 100 and corrected for multiple testing 
1 50 < N < 100 and the number of palliative care patients included was relative to the number of items/variables or N < 50 and corrected for multiple testing 
0 N < 50 or number of palliative care patients included not relative to the number of items/variables or N < 50 and not corrected for multiple testing 
 
 
 
 
 
Validity 
Content validity 2 A description of the construct that is being measured is provided and target population is involved in item selection  
1 A description of the construct that is being measured is provided or target population is involved in item selection 
0 The construct that is being measured is not described and limited / no involvement of target population is involved in item selection 
Criterion validity 2 Correlates acceptable to high (r > .60) according to the 'gold standard' or according to a 'silver standard'  
1 Correlates moderate-acceptable (.40 < r < .60) according to the 'gold standard' or according to a 'silver standard' 
0 Correlates low (r < .40)  
Structural validity 2 Appropriate method of factor analysis performed and factors account for ≥ 50% of the total variance 
1 Factor analysis performed but another method would have been more appropriate 
0 Factors account for < 50% of the total variance  
Construct validity  2 Correlates with other level of consciousness measures acceptable to high (r > .60) 
1 Correlates with other level of consciousness measures are moderate (r > .40 < .60) 
0 Correlates with other level of consciousness measures are low (r < .40)  
 
 
 
 
Reliability 
 
Homogeneity 
(internal consistency) 
2 .70 < alpha < .90 
1 alpha > .90 or .60 < alpha < .70 
0 alpha < .60  
Inter-rater reliability 
 
 
2 Reliability coefficient > .80 
1 .60 < reliability coefficient < .80  
0 Reliability coefficient < .60 
Intra-rater and/or 
Test-retest reliability 
2 Reliability coefficient > .80 
1 .60 < reliability coefficient < .80 
0 Reliability coefficient < .60  
 
 
Responsiveness 2 Appropriate method of detecting clinically meaningful change over time described and clinically meaningful change over time detected and 15% or less of 
respondents achieved the lowest or highest possible score, respectively 
1 Appropriate method of detecting clinically meaningful change over time described and clinically meaningful change over time detected or 15% or less of 
respondents achieved the lowest or highest possible score, respectively 
0 Appropriate method of detecting clinically meaningful change over time not followed or clinically meaningful change over time not detected or more than 15% 
of respondents achieved the lowest or highest possible score, respectively 
 
 
Origin of items 2 Items specifically developed for use with palliative care patients 
1 Items were modified for use with palliative care patients 
0 Items originated from a scale developed for another population 
 Feasibility 2 Scale is short, manageable with instructions, scoring interpretation 
1 Scale is manageable (one format) 
0 Scale is more complex 
23 
 
Table 3: Description of identified studies and measures 
Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Studies reporting ad hoc measures 
Abernethy et 
al.29 
2003 
Australia 
To determine the efficacy of oral 
morphine for the management of 
refractory dyspnoea 
Palliative, 
general, 
respiratory, 
cardiac 
medicine clinics 
48 outpatients 
with refractory 
dyspnoea 
– 
 
To measure sedation depth as a 
side-effect of morphine use 
S: - 
I: 1 
 
4-level scale (‘No’, ‘Mild’, 
‘Moderate’, ‘Severe’ sedation) 
 
Aretha et al.30 
2009 
Greece 
Evaluation of patient/family-
controlled sedation (PFCS) with 
midazolam for intractable symptom 
control 
Tertiary care 
university 
hospital  
8 terminal cancer 
inpatients 
– 
 
Monitoring of patients after 
terminal sedation initiation 
S: - 
I: 1 
 
4-point scale (1= ‘Awake’, 2= 
‘Arousable with voice’, 3= 
‘Arousable with light pain’, 4= 
‘Unarousable’) 
Arevalo et al.31 
2013 
Netherlands 
To describe nurses’ experiences with 
the decision-making and 
performance of continuous palliative 
sedation (CPS) 
Home care 
organisations, 
palliative care 
units (based in 
nursing homes 
or inpatient 
hospices), 
hospitals 
199 nurses 
reporting on their 
last patient 
receiving CPS  
– 
(Scale included in the 
study questionnaire) 
Monitoring of CPS S: - 
I: 1 
 
6-level scale (‘Drowsiness’, ‘Eyes 
closed, reaction to verbal stimuli’, 
‘Eyes closed, reaction to physical 
stimuli’, ‘Eyes closed, no reaction 
to physical stimuli’, ‘Other’, ‘I 
don't know’) 
Barbato32 
2001 
Australia 
Exploration of the clinical application 
of bispectral index (BIS) monitoring 
in palliative care 
Hospice 
 
12 unconscious 
palliative care 
inpatients 
Consciousness Scale 
(modified Glasgow 
Coma Scale33) 
Monitoring of consciousness level 
from the onset of 
unconsciousness and until death 
S: 6 (breathing, 
movement, pulse 
volume, eyelash 
reflex, 
peripheries, 
response to name 
call) 
I: 1/subscale 
 
4-point scale (1-4) for each 
subscale. Scores can be 
calculated per subscale and as a 
total score.  
Baumann et 
al.34 
1986 
USA 
Evaluation of the safety and efficacy 
of patient-controlled analgesia in 
patients with unsuccessfully treated 
chronic pain secondary to cancer 
Not specified 
 
8 terminally ill 
cancer patients 
 
– 
 
To evaluate sedation for the 
assessment of individual 
analgesic response 
S: - 
I: 1 
 
5-point scale (1= ‘Wide awake’, 
2= ‘Drowsy’, 3= ‘Dozing 
intermittently’, 4= ‘Mostly 
sleeping’, 5= ‘Only awakens when 
aroused’) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Dean et al.35 
2014 
UK 
Description of palliative sedation 
decision-making practices in a UK 
hospice over the course of five years 
Hospice 
 
234 patient charts Sedation scale 
(modified Richmond 
Agitation-Sedation 
Scale19) 
Accessing level of sedation to 
guide palliative sedation clinical 
decision-making and 
documentation  
S: - 
I: 1 
 
6-point scale (+2= ‘Agitated/ 
Distressed’, +1= ‘Anxious/ 
Restless’, 0= ‘Alert, orientated, 
calm’, -1= ‘Drowsy: Opening eyes 
and establishing eye contact for 
periods of 10 seconds or more, 
responds to commands’, -2= 
‘Moderate sedation: Rousable to 
voice or physical stimulation. 
Unable to communicate’, -3= 
‘Deep sedation: Unrousable’) 
Fainsinger et 
al.36 
2000 
South Africa, 
Israel, Spain 
To provide a better understanding of 
the use of sedation for the 
management of uncontrolled 
symptoms in terminally ill patients 
Hospices and 
hospital-based 
palliative care 
unit 
387 palliative care 
patients 
– 
 
To assess level of consciousness 
after initiation of sedation for 
uncontrolled symptoms 
S: - 
I: 1 
 
3-level scale  
(‘Alert’, ‘Drowsy’, ‘Unresponsive’) 
Hendricks et 
al.37 
2014 
Netherlands 
To investigate symptoms, treatment 
and quality of life in patients with 
end-stage dementia 
Nursing homes 
 
330 end-stage 
dementia patients 
(213 recruited on 
admission, 117 
retrospectively) 
– 
 
To assess the level of 
consciousness that most 
frequently occurred during the 
last week of life 
S: - 
I: 1 
 
6-level scale  
(‘Awake and alert’, ‘Awake’, 
‘Awake but drowsy looking’, 
‘Falling asleep’, ‘Light sleep’, 
‘Deep looking sleep’) 
Jaspers et al.38  
2012 
Germany 
Description of the practice of 
palliative sedation in Germany 
Palliative care 
units, inpatient 
hospices 
 
1944 electronic 
patient records 
– 
(Depth of palliative 
sedation item 
included in the 
standardised 
documentation 
system for palliative 
care patients) 
To assess depth of palliative 
sedation 
S: - 
I: 1 
 
3-level scale  
(‘Somnolence’, ‘Stupor’, ‘Coma’) 
Morita et al.23 
1998 
Japan 
To investigate the change of physical 
signs and medical interventions in 
the dying process 
Palliative care 
unit 
 
100 terminally ill 
cancer patients 
Categorical scale 
(modified Riker 
Sedation-Agitation 
Scale39) 
To examine changes in the level 
of consciousness in the last four 
weeks of life 
S: - 
I: 1 
 
4-level scale  
(‘Awake: arousable, follows 
commands’, ‘Drowsy: difficult to 
arouse or unable to attend to 
conversation or commands’, 
‘Very drowsy: awakens to 
noxious stimuli only’, ‘Coma: 
does not awaken to any stimuli’) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Morita et al.40 
2000 
Japan 
Identification of risk factors for the 
development and persistency of 
death rattle 
Palliative care 
unit 
 
245 terminally ill 
cancer patients 
(of whom 107 
developed death 
rattle) 
 
Categorical scale 
(modified Riker 
Sedation-Agitation 
Scale39) 
To assess conscious level as a risk 
factor for the 
development/persistency of 
death rattle 
Same as above Same as above 
Morita et al.41 
2003 
Japan 
To investigate the effects of partial 
opioid substitution and hydration on 
the occurrence of agitated delirium 
in the final stage of cancer 
Palliative care 
unit 
 
284 terminally ill 
cancer inpatient 
charts 
Faisinger’s 
consciousness scale  
(Ad hoc scale 
described in Faisinger 
et al.36) 
Evaluation of consciousness level 
as part of the assessment of the 
degree of cognitive impairment 
S: - 
I: 1 
 
3-level scale (‘Alert’, ‘Drowsy’, 
‘Unresponsive’) 
Morita et al.42 
2003 
Japan 
To establish the communication 
capacity level and identify factors 
contributing to communication 
capacity impairment and agitated 
delirium in cancer patients in their 
final week of life 
 
Palliative care 
unit 
 
284 terminally ill 
cancer inpatient 
charts 
 
 
Faisinger’s 
consciousness scale  
(Ad hoc scale 
described in Faisinger 
et al.36) 
Evaluation of consciousness level 
in the last week of life 
Same as above Same as above 
Papavasiliou et 
al.43 
2014 
Belgium 
To compare physician-reported 
practices on continuous deep 
sedation until death (CDSUD) 
between general practitioner and 
medical specialists 
Not specified 
 
561 cases of 
CDSUD reported 
by physicians 
– 
(Level of 
unconsciousness item 
included in 
questionnaire on end-
of-life practices) 
 
Level of unconsciousness 
(comatose) used to assess the 
degree of patients’ awareness 
during the practice of CDSUD 
S: - 
I: 1 
 
11-point scale  
(0= ‘Symptom not present’ to 10= 
‘Worst possible symptom’) 
Pasman et al.44 
2005 
Netherlands 
To study the level and course of 
discomfort, and factors that are 
associated with discomfort in 
patients with dementia for whom 
artificial nutrition and hydration is 
forgone 
 
Nursing homes 
 
178 patients with 
severe dementia 
– 
 
To assess the level of 
consciousness as a determinant 
of discomfort 
S: - 
I: 1 
 
6-point scale  
(response options not described) 
 
Portenoy et 
al.45 
2006 
USA 
Exploration of the relationship 
between opioid use and survival at 
the end-of-life 
Hospices 
 
725 palliative care 
inpatients  
– 
 
Level of consciousness at the 
time of last opioid dose change 
assessed for its association with 
length of survival 
S: - 
I: 1 
 
4-level scale  
(‘Full level of consciousness’, 
‘Drowsy’, ‘Confused’, ‘Unable to 
respond’) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Rys et al.46  
2014 
Belgium 
 
Investigation of the practice of 
continuous sedation until death 
(CSD) in nursing homes 
Nursing homes 
 
249 nurse reports 
of their most 
recent patient 
treated with CSD 
– 
(Depth of sedation 
scale included in the 
study questionnaire) 
To assess depth of sedation 
reached after the administration 
of CSD 
S: - 
I: 1 
 
5-level scale  
(‘Drowsy’, ‘Eyes closed, response 
to voice’, ‘Eyes closed, response 
to painful stimuli’, ‘Eyes closed, 
no reaction to any stimulus’, 
‘Other’) 
 
Swart et al.47 
2012 
Netherlands 
Description of the practice of 
continuous palliative sedation until 
death (CPS) after the introduction of 
a national palliative guideline 
Not specified 
 
370 physicians 
providing 
information about 
their last patient 
who received CPS 
until death 
– 
(Depth of continuous 
sedation item 
included in the study 
questionnaire) 
To assess depth of continuous 
sedation reached after the 
administration of CPS until death 
S: - 
I: 1 
 
5-point scale (‘Drowsy’, ‘Eyes 
closed, responding promptly to 
verbal command’, ‘Eyes closed, 
arousable only by physical 
stimuli’, ‘Eyes closed, not 
arousable by physical stimuli’, 
‘Other’) 
 
van Deijck et 
al.48 
2010 
Netherlands 
Investigation of the practice of 
continuous palliative sedation (CPS) 
in elderly patients 
Nursing homes 
 
316 nursing home 
physicians 
reporting on their 
last case of CPS 
– 
(Level of 
consciousness item 
included in the study 
questionnaire) 
Evaluation of level of 
consciousness at adequate 
symptom relief after the 
administration of CPS 
S: - 
I: 1 
 
6-level scale  
(‘Alert and orientated’, ‘Drowsy’, 
‘Eyes closed, following 
directives’, ‘Eyes closed, 
responding to physical stimuli’, 
‘Eyes closed, not responding to 
physical stimuli’, ‘Disturbed 
brainstem function’) 
 
van Deijck et 
al.49 
2015 
Netherlands 
To explore the characteristics of 
patients with existential suffering 
treated with continuous palliative 
sedation (CPS) and the degree to 
which preconditions for 
administering CPS are fulfilled 
 
Nursing homes 
 
314 cases of 
patients who 
received CPS 
described by 
nursing home 
physicians 
– 
(Level of 
consciousness item 
included in the study 
questionnaire) 
Evaluation of level of 
consciousness at adequate 
symptom relief after the 
administration of CPS 
Same as above Same as above 
Van Der Steen 
et al.50  
2009 
Netherlands  
To compare discomfort in dementia 
patients dying from pneumonia with 
patients dying after intake problems, 
and to assess associations with 
treatment 
 
Nursing homes 
 
725 end-stage 
dementia patients 
 
 
– 
 
To explore the association 
between level of consciousness 
and discomfort 
S: - 
I: 1 
 
6-level scale 
(‘Awake and alert’, ‘Awake’, 
‘Awake but drowsy looking’, 
‘Falling asleep’, ‘Light sleep’, 
‘Deep looking sleep’) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Studies reporting established measures 
Agar et al.51 
2017 
Australia  
To determine the efficacy of 
risperidone or haloperidol relative to 
placebo for delirium symptoms 
among palliative care patients 
Hospice and 
hospital 
palliative care  
inpatient 
services 
247 palliative care 
inpatients with 
various 
diagnoses; 
predominantly 
cancer 
Richmond Agitation-
Sedation Scale 
(RASS)19 
 
To measure sedation as an 
adverse effect of 
risperidone/haloperidol use 
 
S: - 
I: 1 
 
10-point scale (+4= ‘Combative’, 
+3= ‘Very agitation’, +2= 
‘Agitated’, +1= ‘Restless’, 0= 
‘Alert and Calm”, -1= ‘Drowsy’, -
2= ‘Light sedation’, -3= 
‘Moderate sedation’, -4= ‘Deep 
sedation’, -5= ‘Unarousable’) 
Alonso-
Babarro et al.4 
2010 
Spain 
Assessment of the incidence and 
efficacy of palliative sedation (PS) for 
patients who died at home 
Home 
 
245 terminally ill 
cancer patient 
records  
  
Ramsay Sedation 
Scale (RSS)52 
 
 To monitor level of sedation 
after administration of PS 
 
S: - 
I: 1 
 
6-point scale (1= ‘Anxious and 
agitated or restless or both’, 2= 
‘Co-operative, orientated, and 
tranquil, 3= ‘Responds to 
commands only’, 4= ‘Brisk 
response to a light glabellar tap 
or loud auditory stimulus, 5= 
‘Sluggish response’, 6= ‘No 
response’ 
Barbato et al.53 
2017 
Australia 
To determine the validity of the 
Bispectral index monitor and two 
observational scales  
Palliative care 
unit 
 
40 unresponsive 
palliative care 
inpatients 
Richmond Agitation-
Sedation Scale 
(RASS)19 
To assess level of sedation for the 
exploration of the association 
with BIS values 
Same as above Same as above 
Barbato et al.54 
2018 
Australia 
To examine the effectiveness of 
breakthrough medication in 
unresponsive patients and the 
perception of patient comfort made 
by nurses and family 
Palliative care 
unit 
 
40 unresponsive 
palliative care 
inpatients 
Richmond Agitation-
Sedation Scale 
(RASS)19 
To measure level of sedation for 
the assessment of the effect of 
breakthrough 
opioid/benzodiazepine use 
Same as above Same as above 
Benitez-
Rosario et al.55 
2012 
Spain 
To assess the feasibility of a quality 
care project in palliative sedation 
Hospital-based 
palliative care 
service 
204 patient charts 
 
Richmond Agitation-
Sedation Scale 
(RASS)19 
To assess the level of deep 
continuous sedation with the aim 
to reach a predetermined level  
(-5 RASS for patients with 
continuous dyspnoea at rest;  
-4 RASS for delirium or other 
reasons) 
Same as above Same as above 
Boyd and 
Kelly56  
1997 
UK 
Evaluation of the effectiveness of 
oral morphine for the symptomatic 
treatment of dyspnoea in patients 
with advanced cancer 
Home, hospice 
 
15 advanced 
cancer patients 
with dyspnoea 
 
Visual Analogue Scale 
(VAS) 
 
To measure sedation as a side-
effect of oral morphine 
S: - 
I: 1 
 
100mm line anchored by two 
verbal descriptors; 0: ‘Fully 
awake’ to 100: ‘Asleep’ 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Campbell et 
al.57  
2009 
USA 
 
 
To investigate the self-reporting of 
dyspnoea at the very end of life 
Palliative care 
unit 
 
89 palliative care 
inpatients at the 
risk of 
experiencing 
dyspnoea 
Reaction Level Scale 
85 (RLS85)58 
 
To assess consciousness as 
patient characteristic for the 
exploration of the association 
with the ability to self-report 
dyspnoea symptoms 
S: - 
I: 1 
 
8-point scale (1= ‘Alert; No delay 
in response’, 2= ‘Drowsy or 
confused; Responsive to light 
stimulation’, 3= ‘Very drowsy or 
confused; Responsive to strong 
stimulation’ 4= ‘Unconscious; 
Localizes but does not ward off 
pain’, 5= ‘Unconscious; 
Withdrawing movement on pain 
stimulation’, ‘6= Unconscious; 
Stereotype flexion movements 
on pain stimulation’, 7= 
‘Unconscious; Stereotype 
extension movements on pain 
stimulation’, 8= ‘Unconscious; No 
response to pain stimulation’ 
Campbell et 
al.59 
2010 
USA 
To establish the reliability and 
construct validity of a revised 
Respiratory Distress Observation 
Scale (RDOS) 
Palliative care 
unit 
 
89 palliative care 
inpatients at the 
risk of 
experiencing 
dyspnoea 
Reaction Level Scale 
85 (RLS85)58 
 
To assess consciousness for 
ascertaining the construct validity 
of RDOS 
Same as above Same as above 
Campbell et 
al.60  
2013 
USA 
To determine the effect of oxygen 
administration at the very end of life 
Hospice, 
hospital-based 
palliative care 
service 
32 hospice and 
hospital 
inpatients at the 
very end of life 
Reaction Level Scale 
85 (RLS85)58 
 
To measure consciousness for 
the correlation with respiratory 
distress and nearness to death 
Same as above Same as above 
Campbell et 
al.61 2018 
USA 
Determination of the trajectory of 
dyspnoea and respiratory distress 
 
Hospice 91 home-based 
palliative care 
patients 
Reaction Level Scale 
85 (RLS85)58 
 
To measure consciousness for 
the correlation with respiratory 
distress and nearness to death 
Same as above Same as above 
Caraceni et 
al.62 
2018 
Italy 
Comparison of palliative sedation 
practices in home care and hospice 
settings 
 
Home-based 
palliative care 
services, 
hospices 
531 terminal 
cancer patients 
receiving 
palliative sedation 
Modified Wilson 
Sedation Scale 
(MWSS)63  
 
Level of consciousness assessed 
as part of the palliative sedation 
monitoring process 
S: -  
I: 1 
5-point scale (1= ‘Fully awake and 
oriented’, 2= ‘Drowsy but 
rousable’, 3= ‘Eyes closed but 
rousable to command’, 4= ‘Eyes 
closed but rousable to mild 
physical stimulation (earlobe 
tug)’, 5= ‘Eyes closed but 
unrousable to mild physical 
stimulation’ 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
de la Cruz et 
al.64 
2015 
USA 
To describe the prevalence and 
severity of symptoms, including 
delirium, in the final week of life and 
evaluate the usefulness of the 
Nursing Delirium Screening Scale 
(Nu-DESC) 
Hospice 
 
78 terminally ill 
cancer patients 
 
 
Richmond Agitation-
Sedation Scale 
(RASS)19 
 
To measure sedation or agitation 
as the predominant features of 
delirium 
Same as above Same as above 
Franken et 
al.65 
2018 
Netherlands 
To evaluate the variability in 
response to midazolam and to find 
clinically significant covariates that 
predict pharmacodynamic response 
Palliative care 
centre 
43 terminally ill 
inpatients 
receiving 
midazolam 
Ramsay Sedation 
Scale (RSS)52 
To measure the effect of 
midazolam on patients’ sedation 
level 
Same as above Same as above 
Goncalves et 
al.66  
2012 
Portugal 
Description of the sedation practice 
of Portuguese palliative care teams 
Palliative care 
inpatient, home 
care, hospital 
support care 
services 
181 palliative care 
patients (of 
whom 27 
received 
sedation) 
Consciousness Scale 
for Palliative Care 
(CSPC)18 
To assess the deepest 
consciousness level reached after 
the administration of sedation 
S: - 
I: 1 
 
6-point scale (1= ‘Awake’, 2= 
‘Awakens when called by name 
and stays awake during 
discussion’, 3= ‘Awakens but falls 
asleep during discussion’, 4= 
‘Reacts with movement/brief eye 
opening, but without eye 
contact, when called by name’, 
5= ‘Reacts to trapezius muscle 
pinching’, 6 =’Does not react’) 
Goncalves et 
al.67 
2013 
Portugal 
To examine the activity of 
Portuguese palliative care teams 
Inpatient, home 
care and 
hospital 
palliative care 
support care 
services 
164 palliative care 
patients 
Consciousness Scale 
for Palliative Care 
(CSPC)18 
 
Evaluation of consciousness level 
as a patient characteristic 
Same as above Same as above 
Goncalves et 
al.68 
2016 
Portugal 
Comparison of haloperidol alone 
and in combination with midazolam 
for the treatment of acute agitation 
in palliative care 
Palliative care 
unit 
 
79 palliative care 
inpatients 
 
Consciousness Scale 
for Palliative Care 
(CSPC)18 
 
To assess level of consciousness 
when control of agitation is 
reached 
Same as above Same as above 
Hsu et al.69 
2013 
Taiwan 
To investigate the characteristics 
and outcomes of noncancer 
palliative care patients in an acute 
general care setting 
Acute general 
medicine ward 
 
258 inpatients (of 
whom 193 did not 
meet criteria for 
cancer palliative 
care) 
 
Glasgow Coma Scale 
(GCS)33 
To measure Glasgow coma scale 
score as a clinical characteristic 
for the comparison between 
cancer and noncancer patients 
S: 3 (motor 
response, verbal 
response, eye 
opening) 
I: 1/subscale   
Eye opening: 4-point scale (1-4), 
Motor response: 6-point scale  
(1-6), Verbal response: 5-point 
scale (1-5) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Hui et al.21 
2014 
USA, Brazil 
To examine the frequency and onset 
of bedside physical signs and their 
diagnostic performance for 
impending death  
Acute palliative 
care units 
357 advanced 
cancer inpatients 
 
Richmond Agitation-
Sedation Scale 
(RASS)19 
 
Decreased level of consciousness 
(RASS ≤ -2) assessed as a clinical 
sign of impending death 
Same as above Same as above 
Hui et al.70 
2017 
USA 
To compare the effect of lorazepam 
vs placebo as adjuvant to 
haloperidol for persistent agitation 
Acute palliative 
care unit 
 
93 advanced 
cancer inpatients 
with agitated 
delirium 
 
Richmond Agitation-
Sedation Scale 
(RASS)19 
 
To measure sedation and 
agitation for the evaluation of the 
effect of pharmacological 
interventions for the treatment 
of agitation 
Same as above Same as above 
Hwang et al.22  
2013 
South Korea 
To determine the events that herald 
the onset of dying process and 
evaluate their predictive value for 
death within 48 hours 
Palliative care 
unit 
 
181 terminal 
cancer inpatients 
 
 
Alert/Verbal/Painful/
Unresponsive Scale 
(AVPU)71 
 
To measure conscious level as 
clinical sign of impending death 
S: - 
I: 1 
 
4-level scale  
(A= ‘Eyes opened spontaneously, 
orientated speech, obeys 
commands, V= ‘Any verbal, 
motor, or eye response to verbal 
stimulus’, P= ‘Any verbal, motor, 
or eye response to painful 
stimulus’, U= ‘Unresponsive to 
any stimulus’) 
Imai et al.72 
2018 
Japan 
To investigate the effect of two 
types of palliative sedation therapy; 
proportional and deep sedation 
Palliative care 
unit 
 
50 cancer 
inpatients 
Modified Richmond 
Agitation-Sedation 
Scale (RASS)73 
To define deep sedation (RASS ≥ -
4) and the absence of agitation 
(RASS ≤ 0) 
S: - 
I: 1 
 
10-point scale (+4= ‘Combative’ 
to -5= ‘Unarousable’) 
 
Modifications to RASS19:  
-Removal of reference to assisted 
ventilation from definition of 
agitation level 
-Score ‘+1’ can be present in 
patients who are not fully alert 
Klepstad et 
al.74  
2002 
Norway 
Investigation of the relationship 
between patient self-reports of 
cognitive function (CF) and sedation 
with objective assessments of CF 
and sedation 
Hospital-based 
palliative care 
unit 
 
29 cancer 
inpatients 
 
 
Observer's 
Assessment of 
Alertness/Sedation 
(OAA/S)75 
 
To objectively assess sedation 
and compare scores with patient 
self-reports 
S: 4 
(responsiveness, 
speech, facial 
expression, eyes) 
I: 1/subscale 
Responsiveness: 5-point scale   
(1-5), Speech: 4-point scale (2-5), 
Facial expression: 3-point scale 
(3-5), Eyes: 3-point scale (3-5) 
Kohara et al.5  
2005 
Japan 
Investigation of the influence of 
sedative drugs on consciousness 
Hospital-based 
palliative care 
unit 
 
124 terminally ill 
cancer inpatients 
(of whom 63 
received 
sedation) 
Communication 
Capacity Scale- Item 1 
(Conscious level)76 
To compare level of 
consciousness between sedated 
and unsedated patients 
S: - 
I: 1 
(for item 1) 
6-point scale (0= ‘Awake with no 
drowsiness’ to 5= ‘Cannot remain 
awake and cannot be awakened 
by physical stimuli’) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Maltoni et al.77 
2012 
Italy 
Evaluation of the practice of 
palliative sedation (PS) in two Italian 
hospices 
Hospice 
 
327 inpatients (of 
whom 72 
received PS) 
Richmond Agitation-
Sedation Scale 
(RASS)19 
RASS scores used for monitoring 
PS (negativisation of scores proxy 
indicator of the efficacy of PS) 
 
Same as above Same as above 
Masman et 
al.78  
2016 
Netherlands 
To determine the feasibility and 
validity of bispectral index (BIS) 
monitoring in terminally ill patients 
Palliative care 
centre 
 
58 terminally ill 
inpatients 
Ramsay Sedation 
Scale (RSS)52 
 
To assess level of sedation and 
evaluate the correlation between 
Ramsay scores and BIS values 
 
Same as above Same as above 
Matsunuma et 
al.79 
2016 
Japan 
Evaluation of the signs, symptoms, 
and treatments of patients with 
interstitial lung disease (ILD) before 
death 
Community 
hospital  
82 end-stage ILD 
and lung cancer 
inpatient records 
Japan Coma Scale 
(JCS)80 
To determine the frequency of 
loss of consciousness (defined as 
more than 1 point on JCS) before 
death and examine its causes 
S: - 
I: 1 
 
10-point scale (One level (0) for 
‘fully conscious’, 3 levels (1-3) for 
the patient who is ‘awake 
without any stimuli’, 3 levels (10-
30) for the patient who ‘can be 
aroused after stimulation’, 3 
levels (100-300) for the patient 
who ‘cannot be aroused with any 
forceful mechanical stimuli’  
 
McMillan and 
Tittle81  
1995 
USA 
To describe cancer and palliative 
care patients' pain, pain-related side 
effects and the nurses’ assessment 
and responses to these 
Cancer centre, 
hospice home 
care service 
 
44 patients 
treated for pain  
 
Sedation Item of the 
Pain Flow Sheet82 
 
To evaluate level of sedation as a 
opioid-induced side-effect 
S: - 
I: 1 
(for sedation 
item) 
 
5-point scale (0= ‘Fully alert’, 1= 
‘Relaxed, awake’, 2= ‘Drowsy, 
dozing’, 3= ‘Arousable sleep’, 4= 
‘Comatose’) 
Mercadante et 
al.83  
2009 
Italy 
Assessment of the need and the 
effectiveness of sedation for 
intractable symptoms, and the 
thoughts of relatives regarding 
sedation 
Acute pain 
relief and 
palliative care 
unit 
 
77 terminally ill 
cancer patients 
(of whom 42 
received 
sedation) 
 
Communication 
Capacity Scale- Item 1 
(Conscious level)76 
To assess the level of sedation of 
patient after the initiation of 
palliative sedation  
Same as above Same as above 
Mercadante et 
al.84  
2017 
Italy 
To assess the attitudes of palliative 
care clinicians regarding palliative 
sedation at home 
Home 150 physicians 
involved in end of 
life care decisions 
-Richmond Agitation-
Sedation Scale 
(RASS)19 
 
-Ramsay Sedation 
Scale (RSS)52 
 
 
Monitoring of palliative sedation -RASS19: 
Same as above 
 
 
-RSS52: 
Same as above 
 
 
-RASS19: 
Same as above 
 
 
-RSS52: 
Same as above 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
-Rudkin Sedation 
Scale85 
-Rudkin Sedation 
Scale85: 
S: - 
I: 1 
-Rudkin Sedation Scale85: 
5-point scale (1= 'Fully awake’, 2= 
'Drowsy', 3= 'Eyes closed but 
rousable to command', 4= 'Eyes 
closed but rousable to mild 
physical stimulation', 5= 'Eyes 
closed and unrousable to mild 
physical stimulation') 
Mercadante et 
al.86  
2018 
Italy 
To assess the efficacy of Hyoscine 
Butylbromide for the management 
of death rattle 
Hospices  132 cancer 
inpatients with 
reduced level of 
consciousness 
Richmond Agitation-
Sedation Scale - 
Palliative version 
(RASS-PAL)87 
Identification of patients with 
reduced level of consciousness 
(RASS-PAL ≤ -3) 
S: - 
I: 1 
 
10-point scale (+4= ‘Combative’ 
to -5= ‘Unarousable’) 
 
Modifications to RASS19:  
-Descriptors related to ‘pulling 
tubes’/’fighting the ventilator’ 
modified 
-‘Any movement’ refers to eye 
and body 
-‘Physical stimulation’ changed to 
‘gentle physical stimulation’ 
-Clarification on how to score a 
patient with a mixed type 
delirium 
Monreal-
Carrillo et al.88 
2017 
Mexico 
Characterisation of the level of 
consciousness of patients 
undergoing palliative sedation using 
Bispectral index monitoring 
Palliative care 
unit  
20 advanced 
cancer inpatients 
receiving 
palliative sedation 
Ramsay Sedation 
Scale (RSS)52 
Assessment of sedation level 
after initiation of palliative 
sedation  
Same as above Same as above 
Morita et al.76 
2001 
Japan 
Development and validation of the 
Communication Capacity Scale and 
the Agitation Distress scale  
Palliative care 
unit based in a 
cancer institute 
 
30 terminally ill 
cancer inpatients 
with delirium  
-Communication 
Capacity Scale- Item 1 
(Conscious level)76 
 
 
 
-Sedation Scale 
(modified Riker 
Sedation-Agitation 
Scale39) 
To test the association between 
Communication Capacity scores 
and Sedation Scale scores 
-Communication 
Capacity Scale- 
Item 1 (Conscious 
level)76: 
Same as above 
 
-Sedation Scale: 
S: - 
I: 1 
-Communication Capacity Scale- 
Item 1 (Conscious level)76: 
Same as above 
 
 
 
-Sedation Scale: 
4-point scale (0= ‘Calm and 
cooperative’, 1= ‘Over-sedated’, 
2= ‘Very sedated’, 3= 
‘Unrousable’) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Palacio et al.89 
2018 
Colombia 
 
Description of the practice of 
palliative sedation  
Specialised 
palliative care 
unit based in a 
cancer institute 
66 advanced 
cancer inpatients 
undergoing 
palliative sedation 
 
 
Ramsay Sedation 
Scale (RSS)52 
 
Assessment of sedation level 
after initiation of palliative 
sedation 
Same as above Same as above 
Porzio et al.90 
2010 
Italy 
Evaluation of the feasibility and 
efficacy of palliative sedation at 
home 
Home care 
service 
16 terminally ill 
cancer home 
patient charts 
Ramsay Sedation 
Scale (RSS)52 
 
To monitor the level of sedation 
after the administration of PS 
with the aim to reach deep, 
continuous sedation (RSS ≥ 5)  
 
 
Same as above Same as above 
Pype et al.10 
2018 
Belgium 
To explore the practice of 
suboptimal palliative sedation in 
primary care 
Home  7 PC home teams 
and 7 general 
practitioners 
reporting on 27 
cases of palliative 
sedation 
 
 
Richmond Agitation-
Sedation Scale 
(RASS)19 
 
To measure depth of sedation 
throughout the procedure of 
palliative sedation 
Same as above Same as above 
Schmitz et al.91 
2016 
Germany 
To investigate the effectiveness of 
intravenous opioid patient-
controlled therapy (PCT) in reducing 
breathlessness in patients with 
advanced malignant disease 
 
Palliative care 
centre 
 
18 patients with 
moderate or 
severe 
breathlessness 
Richmond Agitation-
Sedation Scale 
(RASS)19 
 
To monitor changes in sedation 
and agitation levels after PCT 
onset 
Same as above Same as above 
van Deijck et 
al.92 
2016 
Netherlands 
To explore which patient-related 
factors at admission are associated 
with receiving continuous palliative 
sedation (CPS) in the terminal phase 
of life 
 
 
 
 
 
Hospices, 
nursing home-
based palliative 
care units 
467 palliative care 
inpatients 
 (of whom 130 
received CPS) 
Glasgow Coma Scale 
(GCS)33 
To evaluate the level of 
consciousness on admission as a 
patient-related characteristic and 
examine its association with CPS 
Same as above Same as above 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Studies reporting measure psychometric properties 
Arevalo et al.93  
2012 
Netherlands 
To study the reliability and validity of 
observer-based sedation scales in 
palliative sedation (PS) 
Hospices, 
nursing home 
 
54 inpatients 
receiving PS 
-Minnesota Sedation 
Assessment Tool 
(MSAT)94  
(Dutch version) 
 
 
 
 
-Richmond Agitation-
Sedation Scale 
(RASS)19  
(Dutch version) 
 
-Vancouver 
Interaction and 
Calmness Scale 
(VICS)95  
(Dutch version) 
 
 
 
 
-Sedation score 
proposed in the 
Guideline for 
Palliative Sedation of 
the Royal Dutch 
Medical Association 
(KNMG)96 
To assess level of consciousness 
before and during the course of 
palliative sedation 
-MSAT94: 
S: 3 (motor 
activity, arousal, 
quality of 
sedation therapy) 
I: 1/subscale 
 
 
-RASS19: 
Same as above 
 
 
-VICS95: 
S: 2 (interaction, 
calmness) 
I: 5/subscale 
 
 
 
 
 
 
 
-KNMG96: 
S: - 
I: 1 
-MSAT94: 
Motor activity: 4 levels (1-4), 
Arousal: 6 levels (1-6), 
Quality of sedation therapy: 3 
levels (‘Adequate’, ‘Oversedated’, 
‘Undersedated’) 
 
 
-RASS19: 
Same as above 
 
- 
VICS95: 
Interaction: 6-point Likert-type 
scale per item (1= ‘Strongly 
disagree’ to 6= ‘Strongly agree’; 
reverse scoring for last item) 
Calmness: 6-point Likert-type 
scale per item (1= ‘Strongly 
disagree’ to 6= ‘Strongly agree’; 
reverse scoring for first item) 
 
 
-KNMG96: 
6-point scale (Level 1: a) ’Awake 
and oriented’, b) ’Drowsy’, c) 
‘Eyes closed, responds promptly 
to verbal commands’, d) ‘Eyes 
closed, arousable only by physical 
stimuli’, Level 2: ‘Eyes closed, not 
arousable by physical stimuli’, 
Level 3: ‘Basic brain functions 
affected’) 
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Author, year 
and country 
Study aim Study setting Study 
population  
Measure name and 
acronym 
Purpose of measure Subscales / 
Number of 
items 
Response options 
Benitez-
Rosario et al.73  
2013 
Spain 
To test the appropriateness and 
reliability of the Richmond Agitation-
Sedation Scale (RASS) in Spanish 
patients with advanced cancer 
 
Palliative care 
unit 
 
156 advanced 
cancer inpatients 
 
Modified Richmond 
Agitation-Sedation 
Scale (RASS)73 
To monitor sedation and 
agitation  
Same as above Same as above 
Bush et al.87 
2014 
Canada 
Exploration of the validity and 
feasibility of a version of the 
Richmond Agitation-Sedation Scale 
(RASS) modified for palliative care 
populations 
Acute palliative 
care unit 
 
10 inpatients with 
agitated delirium 
or receiving 
palliative sedation  
 
Richmond Agitation-
Sedation Scale - 
Palliative version 
(RASS-PAL)87 
To assess the level of sedation 
and agitation 
Same as above Same as above 
Claessens et 
al.97 
2011 
Belgium 
Description of the characteristics of 
palliative care patients receiving 
sedation for the management of 
refractory symptoms 
Palliative care 
units 
 
266 terminally ill 
cancer inpatients 
(of whom 20 
received PS) 
Glasgow Coma Scale 
(GCS)33  
(Dutch version) 
Evaluation of level of 
consciousness at the start and 
during palliative sedation  
S: 3 (motor 
response, verbal 
response, eye 
opening) 
I: 1/subscale 
Eye opening: 4-point scale (1-4), 
Motor response: 6-point scale (1-
6), Verbal response: 5-point scale 
(1-5) 
Claessens et 
al.1  
2012 
Belgium 
To examine the impact of palliative 
sedation (PS) on the level of 
consciousness of terminally ill 
patients 
Palliative care 
units 
 
266 terminally ill 
cancer inpatients 
(of whom 20 
received PS) 
Glasgow Coma Scale 
(GCS)33   
(Dutch version) 
Evaluation of level of 
consciousness with the aim to 
assess the effect of PS  
Same as above Same as above 
Claessens et 
al.98 
2014 
Belgium 
Description of the effect of palliative 
sedation on oral and/or artificial 
food and fluid intake in terminally ill 
patients 
Palliative care 
units 
 
266 terminally ill 
cancer inpatients 
(of whom 20 
received PS) 
Glasgow Coma Scale 
(GCS)33  
(Dutch version) 
To evaluate patients’ level of 
consciousness at admission  
Same as above Same as above 
Goncalves et 
al.18  
2008 
Portugal 
Validation of a consciousness scale 
for palliative care 
Palliative care 
unit 
 
38 advanced 
cancer inpatients 
Consciousness Scale 
for Palliative Care 
(CSPC)18  
To assess level of consciousness S: - 
I: 1 
 
6-point scale (1= ‘Awake’, 2= 
‘Awakens when called by name 
and stays awake during 
discussion’, 3= ‘Awakens but falls 
asleep during discussion’, 4= 
‘Reacts with movement/brief eye 
opening, but without eye 
contact, when called by name’, 
5= ‘Reacts to trapezius muscle 
pinching’, 6 =’Does not react’) 
GCS: Glasgow Coma Scale; RASS: Richmond Agitation-Sedation Scale; RSS: Ramsay Sedation Scale; VAS: Visual Analogue Scale; RLS85: Reaction Level Scale 85; MWSS: Modified Wilson Sedation Scale; CSPC: 
Consciousness Scale for Palliative Care; AVPU: Alert/Verbal/Painful/Unresponsive Scale; OAA/S: Observer's Assessment of Alertness/Sedation; JCS: Japan Coma Scale; RASS-PAL: Richmond Agitation-Sedation Scale - 
Palliative version; MSAT: Minnesota Sedation Assessment Tool; VICS: Vancouver Interaction and Calmness Scale; KNMG: Sedation score proposed in the Guideline for Palliative Sedation of the Royal Dutch Medical 
Association. 
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Table 4: Appraisal of psychometric performance of observational level of consciousness measures 
Measure and 
studies 
Number of 
participants 
Content 
validity 
Criterion 
validity 
Structural 
validity 
Construct 
validity 
Homogeneity 
(internal 
consistency) 
Inter-rater reliability Intra-rater 
and/or Test-
retest reliability 
Responsiveness Origin of 
items 
Feasibility 
Minnesota 
Sedation 
Assessment 
Tool (MSAT) 
(Dutch 
version) 
 
Arevalo et 
al.93 
 
N = 54  
No 
correction 
for multiple 
testing 
Description of 
construct 
provided. No 
involvement 
of target 
population in 
item selection 
Gold 
standard 
not 
available 
NE / NR Assessed 
per subscale  
 
MSATa:  
Spearman’s 
correlation 
coefficient 
ranged from 
0.48 to 0.83 
(mostly 
above 0.60) 
 
MSATm: 
Spearman’s 
correlation 
coefficient 
ranged from 
0.42 to 0.61 
 
NE / NR Assessed per subscale  
 
 
MSATa:  
ICC ranged from 0.59 
(95% CI: 0.45-0.70) to 
0.64 (95% CI: 0.46-
0.77) depending on 
time difference 
between paired 
assessments 
 
MSATm:  
ICC ranged from 0.01 
(95% CI: -0.25-0.25) 
to 0.11 (95% CI: -0.09-
0.29) depending on 
time difference 
between paired 
assessments  
 
MSATq:  
Cohen's kappa ranged 
from 0.436 to 0.545 
depending on time 
difference between 
paired assessments 
 
 
NE / NR NE / NR Items 
originated 
from a scale 
developed for 
another 
population 
Evaluated as 
clear and easy 
to use (when 
compared with 
the Dutch 
versions of 
RASS and VICS) 
Rating 1 1 
 
 
– 
 
– 
 
MSATa: 2 
MSATm: 1 
– 
 
MSATa: 1 
MSATm: 0 
MSATq: 0 
– 
 
– 
 
0 2 
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Measure and 
studies 
Number of 
participants 
Content 
validity 
Criterion 
validity 
Structural 
validity 
Construct 
validity 
Homogeneity 
(internal 
consistency) 
Inter-rater reliability Intra-rater 
and/or Test-
retest reliability 
Responsiveness Origin of 
items 
Feasibility 
Vancouver 
Interaction 
and Calmness 
Scale (VICS) 
(Dutch 
version) 
 
Arevalo et 
al.93 
 
N = 54   
No 
correction 
for multiple 
testing 
Description of 
construct 
provided. No 
involvement 
of target 
population in 
item selection 
Gold 
standard 
not 
available 
NE / NR Assessed 
per subscale  
 
VICSi: 
Spearman’s 
correlation 
coefficient 
ranged from 
0.31 to 0.72 
(mostly 
above 0.40) 
 
VICSc:  
Spearman’s 
correlation 
coefficient 
ranged from 
0.31 to 0.57 
(mostly 
above 0.40) 
 
NE / NR Assessed per subscale  
 
 
VICSi:  
ICC ranged from 0.77 
(95% CI: 0.64-0.86) to 
0.85 (95% CI: 0.73-
0.92) depending on 
time difference 
between paired 
assessments 
 
VICSc: 
ICC ranged from 0.12 
(95% CI: -0.18-0.40) 
to 0.34 (95% CI: 0.1-
0.52) depending on 
time difference 
between paired 
assessments 
NE / NR NE / NR Items 
originated 
from a scale 
developed for 
another 
population 
Evaluated as 
the least clear 
and easy to use 
(when 
compared with 
the Dutch 
versions of 
RASS and 
MSAT) 
Rating 1 1 – 
 
– 
 
VICSi: 1 
VICSc: 1 
– 
 
VICSi: 2 
VICSc: 0 
– 
 
– 
 
0 1 
Richmond 
Agitation-
Sedation 
Scale (RASS) 
(Dutch 
version) 
 
Arevalo et 
al.93 
 
N = 54  
No 
correction 
for multiple 
testing 
Description of 
construct 
provided. No 
involvement 
of target 
population in 
item selection 
Gold 
standard 
not 
available 
NE / NR Spearman’s 
correlation 
coefficient 
ranged from 
0.57 to 0.84 
 
NE / NR ICC ranged from 0.71 
(95% CI: 0.60-0.79) to 
0.73 (95% CI: 0.58-
0.83) depending on 
time difference 
between paired 
assessments 
NE / NR NE / NR Items 
originated 
from a scale 
developed for 
another 
population 
Evaluated as 
the least time-
consuming, 
clearest and 
easiest to use 
(when 
compared with 
Dutch MSAT 
and VICS) 
 
 
 
 
Rating 1 1 – – 2 – 1 – – 0 2 
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Measure and 
studies 
Number of 
participants 
Content 
validity 
Criterion 
validity 
Structural 
validity 
Construct 
validity 
Homogeneity 
(internal 
consistency) 
Inter-rater reliability Intra-rater 
and/or Test-
retest reliability 
Responsiveness Origin of 
items 
Feasibility 
Sedation 
score 
proposed in 
the Guideline 
for Palliative 
Sedation of 
the Royal 
Dutch Medical 
Association 
(KNMG) 
 
Arevalo et 
al.93 
 
N = 54 
No 
correction 
for multiple 
testing 
 
 
 
 
 
 
 
 
 
 
 
 
Description of 
construct 
provided. No 
involvement 
of target 
population in 
item selection 
Gold 
standard 
not 
available 
NE / NR Spearman’s 
correlation 
coefficient 
ranged from 
0.44 to 0.84 
NE / NR ICC ranged from 0.66 
(95% CI: 0.54-0.76) to 
0.71 (95% CI: 0.55-
0.82) depending on 
time difference 
between paired 
assessments 
 
 
 
 
 
 
 
 
 
NE / NR NE / NR Measure 
specifically 
developed for 
use with 
palliative care 
patients 
 
 
 
 
 
 
 
 
 
 
NE / NR 
Rating 
 
1 1 – 
 
– 
 
2 – 
 
1 – 
 
– 
 
2 – 
 
Modified 
Richmond 
Agitation-
Sedation 
Scale (RASS) 
 
Benitez-
Rosario et 
al.73 
N = 156  Description of 
construct 
provided. 
Target 
population 
involved in 
item 
modification 
Gold 
standard 
not 
available 
NE / NR Spearman’s 
correlation 
coefficient 
ranged from 
0.81 to 0.89 
(P < 0.001) 
 
 
NE / NR Weighted Cohen's 
kappa ranged from 
0.85 (95% CI: 0.85-
0.92) to 0.95 (95% CI: 
0.91-0.98) 
NE / NR Not adequate 
information 
provided 
Items 
modified for 
use with 
palliative care 
patients 
 
Reported as a 
very useful, 
manageable 
tool that could 
facilitate fluid 
communication 
among the PC 
team  
Rating 2 2 – 
 
– 
 
2 – 
 
2 – 
 
– 
 
1 2 
39 
 
Measure and 
studies 
Number of 
participants 
Content 
validity 
Criterion 
validity 
Structural 
validity 
Construct 
validity 
Homogeneity 
(internal 
consistency) 
Inter-rater reliability Intra-rater 
and/or Test-
retest reliability 
Responsiveness Origin of 
items 
Feasibility 
Richmond 
Agitation-
Sedation 
Scale - 
Palliative 
version (RASS-
PAL) 
 
Bush et al.87 
N = 10  
No 
correction 
for multiple 
testing 
Description of 
construct 
provided. 
Target 
population 
involved in 
item 
modification 
Gold 
standard 
not 
available 
NE / NR NE / NR NE / NR ICC ranged from 0.84 
(95% CI: 0.56-0.95) to 
0.98 (95% CI: 0.95-
1.00) 
NE / NR NE / NR Items 
modified for 
use with 
palliative care 
patients 
Evaluated as 
easy to use, 
simple and brief 
Rating 0 2 – – 
 
– 
 
– 
 
2 – 
 
– 
 
1 2 
Glasgow 
Coma Scale 
(GCS) (Dutch 
version) 
Claessens et 
al.1,97,98 
N = 266  Description of 
construct 
provided. No 
involvement 
of target 
population in 
item selection 
Gold 
standard 
not 
available 
NE / NR NE / NR NE / NR ICC = 0.807  
(CI= 0.671-0.891;  
P = 0.000) 
NE / NR NE / NR Items 
originated 
from a scale 
developed for 
another 
population 
NE / NR 
Rating 2 
 
1 – 
 
– 
 
– 
 
– 
 
2 
 
– 
 
– 
 
0 – 
 
Consciousness 
Scale for 
Palliative Care 
(CSPC) 
 
Goncalves et 
al.18 
 
N = 38  
No 
correction 
for multiple 
testing 
Description of 
construct 
provided. 
Target 
population 
involved in 
item selection 
Gold 
standard 
not 
available 
NE / NR Spearman’s 
correlation 
coefficient 
ranged from 
0.88 to 0.98 
(P < 0.001) 
 
 
Cronbach's α 
= 0.99 
ICC = 0.99 (P < 0.001) NE / NR NE / NR Scale 
specifically 
developed for 
use with 
palliative care 
patients 
Evaluated as 
easy to use and 
useful in clinical 
practice 
Rating 0 
 
2 – 
 
– 
 
2 2 2 – 
 
– 
 
2 2 
NE: Not evaluated; NR: Not reported; MSAT: Minnesota Sedation Assessment Tool; MSATa: Minnesota Sedation Assessment Tool arousal subscale;  MSATm: Minnesota Sedation Assessment 
Tool motor activity subscale; ICC: Intraclass Correlation Coefficient; VICS: Vancouver Interaction and Calmness Scale; VICSi: Vancouver Interaction and Calmness Scale interaction subscale; 
VICSc: Vancouver Interaction and Calmness Scale calmness subscale; RASS: Richmond Agitation-Sedation Scale, KNMG: Sedation score proposed in the Guideline for Palliative Sedation of the 
Royal Dutch Medical Association, RASS-PAL: Richmond Agitation-Sedation Scale - Palliative version, GCS: Glasgow Coma Scale, CSPC: Consciousness Scale for Palliative Care. 
